|
1
|
Shaw JE, Sicree RA and Zimmet PZ: Global
estimates of the prevalence of diabetes for 2010 and 2030. Diabetes
Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee CD, Folsom AR, Pankow JS and Brancati
FL; Atherosclerosis Risk in Communities (ARIC) Study Investigators,
: Cardiovascular events in diabetic and nondiabetic adults with or
without history of myocardial infarction. Circulation. 109:855–860.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Knapp M, Tu X and Wu R: Vascular
endothelial dysfunction, a major mediator in diabetic
cardiomyopathy. Acta Pharmacol Sin. 40:1–8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Escaned J, Colmenárez H, Ferrer MC,
Gutiérrez M, Jiménez-Quevedo P, Hernández R, Alfonso F, Bañuelos C,
Deisla LP, Zamorano JL and Macaya C: Diastolic dysfunction in
diabetic patients assessed with Doppler echocardiography:
Relationship with coronary atherosclerotic burden and
microcirculatory impairment. Rev Esp Cardiol. 62:1395–1403. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng X, Sun T and Wang X: Activation of
type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation
through the SIRT1/PGC-1α pathway. Biochem Biophys Res Commun.
436:377–381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun X, Chen RC, Yang ZH, Sun GB, Wang M,
Ma XJ, Yang LJ and Sun XB: Taxifolin prevents diabetic
cardiomyopathy in vivo and in vitro by inhibition of oxidative
stress and cell apoptosis. Food Chem Toxicol. 63:221–232. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rowe GC, Jiang A and Arany Z: PGC-1
coactivators in cardiac development and disease. Circ Res.
107:825–838. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arany Z, He H, Lin J, Hoyer K, Handschin
C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, et al: Transcriptional
coactivator PGC-1 alpha controls the energy state and contractile
function of cardiac muscle. Cell Metab. 1:259–271. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sebastiani M, Giordano C, Nediani C,
Travaglini C, Borchi E, Zani M, Feccia M, Mancini M, Petrozza V,
Cossarizza A, et al: Induction of mitochondrial biogenesis is a
maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll
Cardiol. 50:1362–1369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koh JH, Hancock CR, Terada S, Higashida K,
Holloszy JO and Han DH: PPARβ is essential for maintaining normal
levels of PGC-1α and mitochondria and for the increase in muscle
mitochondria induced by exercise. Cell Metab. 25:1176–1185.e5.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Z, Puigserver P, Andersson U, Zhang C,
Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC and
Spiegelman BM: Mechanisms controlling mitochondrial biogenesis and
respiration through the thermogenic coactivator PGC-1. Cell.
98:115–124. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura H, Matoba S, Iwai-Kanai E, Kimata
M, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Ariyoshi M, Mita Y,
et al: p53 promotes cardiac dysfunction in diabetic mellitus caused
by excessive mitochondrial respiration-mediated reactive oxygen
species generation and lipid accumulation. Circ Heart Fail.
5:106–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anderson EJ, Rodriguez E, Anderson CA,
Thayne K, Chitwood WR and Kypson AP: Increased propensity for cell
death in diabetic human heart is mediated by
mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol.
300:H118–H124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mei M, Tang F, Lu M, He X, Wang H, Hou X,
Hu J, Xu C and Han R: Astragaloside IV attenuates apoptosis of
hypertrophic cardiomyocyte through inhibiting oxidative stress and
calpain-1 activation. Environ Toxicol Pharmacol. 40:764–773. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S, Tang F, Yang Y, Lu M, Luan A,
Zhang J, Yang J and Wang H: Astragaloside IV protects against
isoproterenol-induced cardiac hypertrophy by regulating
NF-κB/PGC-1α signaling mediated energy biosynthesis. PLoS One.
10:e01187592015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jia G, Leng B, Wang H and Dai H:
Inhibition of cardiotrophin-1 overexpression is involved in the
anti-fibrotic effect of Astrogaloside IV. Mol Med Rep.
16:8365–8370. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai H, Jia G, Lu M, Liang C, Wang Y and
Wang H: Astragaloside IV inhibits isoprenaline-induced cardiac
fibrosis by targeting the reactive oxygen species/mitogen-activated
protein kinase signaling axis. Mol Med Rep. 15:1765–1770. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu C, Tang F, Lu M, Yang J, Han R, Mei M,
Hu J and Wang H: Pretreatment with Astragaloside IV protects human
umbilical vein endothelial cells from hydrogen peroxide induced
oxidative stress and cell dysfunction via inhibiting eNOS
uncoupling and NADPH oxidase-ROS-NF-κB pathway. Can J Physiol
Pharmacol. 94:1132–1140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu C, Tang F, Lu M, Yang J, Han R, Mei M,
Hu J, Zhou M and Wang H: Astragaloside IV improves the
isoproterenol-induced vascular dysfunction via attenuating eNOS
uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB
pathways. Int Immunopharmacol. 33:119–127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu M, Tang F, Zhang J, Luan A, Mei M, Xu
C, Zhang S, Wang H and Maslov LN: Astragaloside IV attenuates
injury caused by myocardial ischemia/reperfusion in rats via
regulation of toll-like receptor 4/nuclear factor-κB signaling
pathway. Phytother Res. 29:599–606. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holly EN, Shimamoto A, Debold JF and
Miczek KA: Sex differences in behavioral and neural
cross-sensitization and escalated cocaine taking as a result of
episodic social defeat stress in rats. Pyschopharmacology (Berl).
224:179–188. 2012. View Article : Google Scholar
|
|
22
|
Walczak M and Błasiak T: Midbrain
dopaminergic neuron activity across alternating brain states of
urethane anaesthetized rat. Eur J Neurosci. 45:1068–1077. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seferović PM, Petrie MC, Filippatos GS,
Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino
F, de Boer RA, et al: Type 2 diabetes mellitus and heart failure: A
position statement from the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail. 20:853–872. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amos AF, McCarty DJ and Zimmet P: The
rising global burden of diabetes and its complications: Estimates
and projections to the year 2010. Diabet Med. 14 (Suppl 5):S1–S85.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dries DL, Sweitzer NK, Drazner MH,
Stevenson LW and Gersh BJ: Prognostic impact of diabetes mellitus
in patients with heart failure according to the etiology of left
ventricular systolic dysfunction. J Am Coll Cardiol. 38:421–428.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kannel WB, Hjortland M and Castelli WP:
Role of diabetes in congestive heart failure: The framingham study.
Am J Cardiol. 34:29–34. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alaei Faradonbeh N, Nikaeen F, Akbari M,
Almasi N and Vakhshoori M: Cardiovascular disease risk prediction
among Iranian patients with diabetes mellitus in Isfahan Province,
Iran, in 2014, by using Framingham risk score, atherosclerotic
cardiovascular disease risk score, and high-sensitive C-reactive
protein. ARYA Atheroscler. 14:163–168. 2018.PubMed/NCBI
|
|
28
|
Tadic M and Cuspidi C: Obesity and heart
failure with preserved ejection fraction: A paradox or something
else? Heart Fail Rev. 24:379–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Icks A, Claessen H, Kirchberger I, Heier
M, Peters A, Trentinaglia I, Giani G, von Scheidt W and Meisinger
C: Mortality after first myocardial infarction in diabetic and
non-diabetic people between 1985 and 2009. The MONICA/KORA
registry. Eur J Epidemiol. 29:899–909. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feuvray D: Diabetic cardiomyopathy. Arch
Mal Coeur Vaiss. 97:261–265. 2004.PubMed/NCBI
|
|
31
|
Boudina S and Abel ED: Diabetic
cardiomyopathy revisited. Circulation. 115:3213–3223. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fiordaliso F, Li B, Latini R, Sonnenblick
EH, Anversa P, Leri A and Kajstura J: Myocyte death in
streptozotocin-induced diabetes in rats in angiotensin
II-dependent. Lab Invest. 80:513–527. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Di Carli MF, Janisse J, Grunberger G and
Ager J: Role of chronic hyperglycemia in the pathogenesis of
coronary microvascular dysfunction in diabetes. J Am Coll Cardiol.
41:1387–1393. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Riehle C and Bauersachs J: Of mice and
men: Models and mechanisms of diabetic cardiomyopathy. Basic Res
Cardiol. 114:22018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gilca GE, Stefanescu G, Badulescu O,
Tanase DM, Bararu I and Ciocoiu M: Diabetic cardiomyopathy: Current
approach and potential diagnostic and therapeutic targets. J
Diabetes Res. 2017:13102652017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Voulgari C, Papadogiannis D and
Tentolouris N: Diabetic cardiomyopathy: From the pathophysiology of
the cardiac myocytes to current diagnosis and management
strategies. Vasc Health Risk Manag. 6:883–903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu M, Leng B, He X, Zhang Z, Wang H and
Tang F: Calcium sensing receptor-related pathway contributes to
cardiac injury and the mechanism of Astragaloside IV on
cardioprotection. Front Pharmacol. 9:11632018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guan FY, Yang SJ, Liu J and Yang SR:
Effect of astragaloside IV against rat myocardial cell apoptosis
induced by oxidative stress via mitochondrial ATP-sensitive
potassium channels. Mol Med Rep. 12:371–376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kakoullis L, Giannopoulou E,
Papachristodoulou E, Pantzaris ND, Karamouzos V, Kounis NG, Koniari
I and Velissaris D: The utility of brain natriuretic peptides in
septic shock as markers for mortality and cardiac dysfunction: A
systematic review. Int J Clin Pract. 73:e133742019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pemberton CJ, Johnson ML, Yandle TG and
Espiner EA: Deconvolution analysis of cardiac natriuretic peptides
during acute volume overload. Hypertension. 36:355–359. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tang WH, Francis GS, Morrow DA, Newby LK,
Cannon CP, Jesse RL, Storrow AB and Christenson RH; NACB Committee,
: National academy of clinical biochemistry laboratory medicine
practice guidelines: Clinical utilization of cardiac biomarker
testing in heart failure. Clin Biochem. 41:210–221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li S, Xiao Z, Li L, Hu B, Zhou Z, Yi S,
Luo J, Xie L, Nie B, Mo L and Wang S: Establishment of normal
reference values of NT-proBNP and its application in diagnosing
acute heart failure in children with severe hand food and mouth
disease. Medicine. 97:e122182018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Candido R, Forbes JM, Thomas MC, Thallas
V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME
and Burrell LM: A breaker of advanced glycation end products
attenuates diabetes-induced myocardial structural changes. Circ
Res. 92:785–792. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Connelly KA, Kelly DJ, Zhang Y, Prior DL,
Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, et al:
Functional, structural and molecular aspects of diastolic heart
failure in the diabetic (mRen-2)27 rat. Cardiovasc Res. 76:280–291.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ritchie RH, Quinn JM, Cao AH, Drummond GR,
Kaye DM, Favaloro JM, Proietto J and Delbridge LM: The antioxidant
tempol inhibits cardiac hypertrophy in the insulin-resistant
GLUT4-deficient mouse in vivo. J Mol Cell Cardiol. 42:1119–1128.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huynh K, McMullen JR, Julius TL, Tan JW,
Love JE, Cemerlang N, Kiriazis H, Du XJ and Ritchie RH:
Cardiac-specific IGF-1 receptor transgenic expression protects
against cardiac fibrosis and diastolic dysfunction in a mouse model
of diabetic cardiomyopathy. Diabetes. 59:1512–1520. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Das DK: Redox regulation of cardiomyocyte
survival and death. Antioxid Redox Signal. 3:23–37. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Webster KA, Graham RM and Bishopric NH:
BNip3 and signal-specific programmed death in the heart. J Mol Cell
Cardiol. 38:35–45. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Das S, Khan N, Mukherjee S, Bagchi D,
Gurusamy N, Swartz H and Das DK: Redox regulation of
resveratrol-mediated switching of death signal into survival
signal. Free Radic Biol Med. 44:82–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lax NZ, Turnbull DM and Reeve AK:
Mitochondrial mutations: Newly discovered players in neuronal
degeneration. Neuroscientist. 17:645–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li XD, Li XM, Gu JW and Sun XC: MiR-155
regulates lymphoma cell proliferation and apoptosis through
targeting SOCS3/JAK-STAT3 signaling pathway. Eur Rev Med Pharmacol
Sci. 21:5153–5159. 2017.PubMed/NCBI
|
|
52
|
Fetterman JL, Holbrook M, Westbrook DG,
Brown JA, Feeley KP, Bretón-Romero R, Linder EA, Berk BD, Weisbrod
RM, Widlansky ME, et al: Mitochondrial DNA damage and vascular
function in patients with diabetes mellitus and atherosclerotic
cardiovascular disease. Cardiovasc Diabetol. 15:532016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kalvala AK, Khan I, Gundu C and Kumar A:
An overview on ATP dependent and independent proteases including an
anterograde to retrograde control on mitochondrial function; Focus
on diabetes and diabetic complications. Curr Pharm Des. Jul
18–2019.(Epub ahead of print). doi:
10.2174/1381612825666190718153901. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jin H, Zhu B, Liu X, Jin J and Zou H:
Metabolic characterization of diabetic retinopathy: An
1H-NMR-based metabolomic approach using human aqueous
humor. J Pharm Biomed Anal. 174:414–421. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rolfe DF and Brown GC: Cellular energy
utilization and molecular origin of standard metabolic rate in
mammals. Physiol Rev. 77:731–758. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Trost SU, Belke DD, Bluhm WF, Meyer M,
Swanson E and Dillmann WH: Overexpression of the sarcoplasmic
reticulum Ca(2+)-ATPase improves myocardial contractility in
diabetic cardiomyopathy. Diabetes. 51:1166–1171. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Camara AK, Bienengraeber M and Stowe DF:
Mitochondrial approaches to protect against cardiac ischemia and
reperfusion injury. Front Physiol. 2:132011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chatham JC and Seymour AM: Cardiac
carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovasc
Res. 55:104–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dey S, DeMazumder D, Sidor A, Foster DB
and O'Rourke B: Mitochondrial ROS drive sudden cardiac death and
chronic proteome remodeling in heart failure. Circ Res.
123:356–371. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang Y, Gao P, Wei C, Li H, Zhang L, Zhao
Y, Wu B, Tian Y, Zhang W, Wu L, et al: Calcium sensing receptor
protects high glucose-induced energy metabolism disorder via
blocking gp78-ubiquitin proteasome pathway. Cell Death Dis.
8:e27992017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ares-Carrasco S, Picatoste B, Camafeita E,
Carrasco-Navarro S, Zubiri I, Ortiz A, Egido J, López JA, Tuñón J
and Lorenzo O: Proteome changes in the myocardium of experimental
chronic diabetes and hypertension: Role of PPARα in the associated
hypertrophy. J Proteomics. 75:1816–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tsushima K, Bugger H, Wende AR, Soto J,
Jenson GA, Tor AR, McGlauflin R, Kenny HC, Zhang Y, Souvenir R, et
al: Mitochondrial reactive oxygen species in lipotoxic hearts
induce Post-translational modifications of AKAP121, DRP1, and OPA1
that promote mitochondrial fission. Circ Res. 122:58–73. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Knowlton AA, Chen L and Malik ZA: Heart
failure and mitochondrial dysfunction: The role of mitochondrial
fission/fusion abnormalities and new therapeutic strategies. J
Cardiovasc Pharmacol. 63:196–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Song M, Mihara K, Chen Y, Scorrano L and
Dorn GW II: Mitochondrial fission and fusion factors reciprocally
orchestrate mitophagic culling in mouse hearts and cultured
fibroblasts. Cell Metab. 21:273–286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Recchia FA, McConnell PI, Bernstein RD,
Vogel TR, Xu X and Hintze TH: Reduced nitric oxide production and
altered myocardial metabolism during the decompensation of
pacing-induced heart failure in the conscious dog. Circ Res.
83:969–979. 1998. View Article : Google Scholar : PubMed/NCBI
|
